Categories: Health

AVITA Medical to Host Investor Webinar Briefing

 | Source: AVITA Medical

VALENCIA, Calif., Aug. 10, 2025 (GLOBE NEWSWIRE) — AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Jim Corbett, Chief Executive Officer, and David O’Toole, Chief Financial Officer, on August 14, 2025, at 9 AM Australian Eastern Daylight Time (August 13 at 4 PM U.S. Pacific Standard Time).

The webinar presentation will cover financial and business results from our recent second-quarter 2025 earnings webcast and will conclude with a Q&A session. Participants are invited to submit their questions via the registration page.

Register: https://us06web.zoom.us/webinar/register/WN_LkikThGHT0yE-xWNoH6bRw

A replay will be available on the AVITA Medical website, ir.avitamedical.com, following the presentation.

About AVITA Medical, Inc.

AVITA Medical® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL® System, approved by the FDA for the treatment of thermal burn and trauma wounds. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin™ Cells, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the exclusive rights to manufacture, market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix, and the exclusive rights to market, sell, and distribute Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix.

In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including thermal burns and trauma wounds. The RECELL System, excluding RECELL GO®, is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan.

To learn more, visit www.avitamedical.com.

Investor & Media Contact:
Ben Atkins
Phone +1-805 341 1571
investor@avitamedical.com
media@avitamedical.com

Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.

GlobeNews Wire

Recent Posts

EDC supports first loan in South Korea with $200 million in financing for Lotte Shopping

This marks the inaugural deal under the EDC-Lotte Market Leader Partnership (MLP) program OTTAWA, ON,…

7 hours ago

Future Minerals Forum Unveils Three-Day Program for Its 5th Largest Edition

RIYADH, Saudi Arabia, Nov. 21, 2025 /PRNewswire/ -- The Future Minerals Forum (FMF), convened by…

8 hours ago

Conavi Medical Corp. Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants

November 21, 2025 16:30 ET  | Source: Conavi Medical Corp. PRELIMINARY PROSPECTUS ACCESSIBLE ON SEDAR+…

9 hours ago

Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference

November 21, 2025 16:06 ET  | Source: Supernus Pharmaceuticals, Inc. ROCKVILLE, Md., Nov. 21, 2025…

9 hours ago

CGTN: G20 lands in Africa: China calls for unity over division

BEIJING, Nov. 23, 2025 /PRNewswire/ -- CGTN published an article on the G20 summit's first…

9 hours ago

Flock Safety Receives Frost & Sullivan’s 2025 North American New Product Innovation Recognition for Excellence in Mobile Security

Recognized for redefining mobile security through innovative, customer-centric solutions that enhance situational awareness and operational…

9 hours ago